Healthcare

Healius (ASX:HLS) reported improved underlying operating performance in FY26 while managing restructuring outcomes,Impairmentcharges and a cautious FY27 outlook. The company has progressed cost reduction initiatives and margin improvements, with future performance dependent on continued operational recovery.

• Epiminder Ltd changed hands at $0.435 at 15:17 AEST on Wednesday 19 August 2026, up 4.82% on the day.

Argenica Therapeutics (ASX:AGN) is progressing the development pathway for its lead asset ARG-007, now known as xaranetide, as the company works through regulatory requirements and Phase 2b stroke trial planning. The programme remains focused on addressing the USFood and Drug Administration (FDA)clinical hold requirements …

Cochlear (ASX:COH) is heading into FY27 with its growth strategy increasingly anchored to two things: the continued rollout of its Nucleus Nexa System and a push to fix long-standing gaps in how adult patients get referred for cochlear implants in the US. Both will …

CSL Limited (ASX:CSL) has described FY26 as a “reset year,” and the company’s FY27 outlook is effectively the test of that reset. After absorbing largeImpairmentand restructuring charges, CSL is now guiding toward a return toEarningsgrowth, with the trajectory of its core businesses — Behring, …

On cost, the study's primary endpoint, PermeaDerm achieved a mean treatment cost of $148.70 per 1% of total body surface area (TBSA) treated, compared with $497.10 for allograft. That represents a saving of approximately $348 per percentage point of TBSA and a 70% lower …

TheEarningsdecline came from higher depreciation,Amortisationand financing costs tied to the company's now-completed four-year, $360 million distribution centre renewal program. That investment has created a modern, efficient infrastructure base, and the worst earnings drag is now behind the company. FY27 capital expenditure is forecast to …